Published in Mol Cell Biol on August 01, 1999
MYC on the path to cancer. Cell (2012) 8.65
Evaluation of myc E-box phylogenetic footprints in glycolytic genes by chromatin immunoprecipitation assays. Mol Cell Biol (2004) 2.19
MYC, metabolism, cell growth, and tumorigenesis. Cold Spring Harb Perspect Med (2013) 2.19
Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood (2010) 1.76
Overexpression of MYC causes p53-dependent G2 arrest of normal fibroblasts. Proc Natl Acad Sci U S A (2000) 1.70
Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase. Proc Natl Acad Sci U S A (2010) 1.65
Estrogen mediates Aurora-A overexpression, centrosome amplification, chromosomal instability, and breast cancer in female ACI rats. Proc Natl Acad Sci U S A (2004) 1.50
BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J Exp Med (2011) 1.45
Involvement of Myc activity in a G(1)/S-promoting mechanism parallel to the pRb/E2F pathway. Mol Cell Biol (2000) 1.34
c-Myc accelerates S-phase and requires WRN to avoid replication stress. PLoS One (2009) 1.32
Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression. Proc Natl Acad Sci U S A (2003) 1.27
A role for polyploidy in the tumorigenicity of Pim-1-expressing human prostate and mammary epithelial cells. PLoS One (2008) 1.14
Myc: the beauty and the beast. Genes Cancer (2010) 1.07
c-myc and N-myc promote active stem cell metabolism and cycling as architects of the developing brain. Oncotarget (2010) 1.07
Overexpression of c-Myc alters G(1)/S arrest following ionizing radiation. Mol Cell Biol (2002) 1.04
Polycomb proteins control proliferation and transformation independently of cell cycle checkpoints by regulating DNA replication. Nat Commun (2014) 1.03
Three steps to the immortality of cancer cells: senescence, polyploidy and self-renewal. Cancer Cell Int (2013) 1.01
MYC prevents apoptosis and enhances endoreduplication induced by paclitaxel. PLoS One (2009) 0.98
A subset of Drosophila Myc sites remain associated with mitotic chromosomes colocalized with insulator proteins. Nat Commun (2013) 0.97
c-Myc suppression of DNA double-strand break repair. Neoplasia (2012) 0.95
c-Myc-mediated genomic instability proceeds via a megakaryocytic endomitosis pathway involving Gp1balpha. Proc Natl Acad Sci U S A (2007) 0.94
c-Myc alters the DNA damage-induced G2/M arrest in human mammary epithelial cells. Br J Cancer (2003) 0.94
Global regulation of genome duplication in eukaryotes: an overview from the epifluorescence microscope. Chromosoma (2008) 0.94
Transcriptional control of DNA replication licensing by Myc. Sci Rep (2013) 0.89
c-MYC-induced genomic instability. Cold Spring Harb Perspect Med (2014) 0.89
MYC Is a Major Determinant of Mitotic Cell Fate. Cancer Cell (2015) 0.88
A truncated isoform of the protein phosphatase 2A B56gamma regulatory subunit may promote genetic instability and cause tumor progression. Am J Pathol (2003) 0.87
Focal chromosomal copy number aberrations identify CMTM8 and GPR177 as new candidate driver genes in osteosarcoma. PLoS One (2014) 0.84
A Novel Secreted Protein, MYR1, Is Central to Toxoplasma's Manipulation of Host Cells. MBio (2016) 0.81
Transgenerational cell fate profiling: a method for the graphical presentation of complex cell cycle alterations. Cell Cycle (2012) 0.79
Cancer stem cells and cell size: A causal link? Semin Cancer Biol (2015) 0.79
Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma. Oncotarget (2015) 0.77
Somatic polyploidy is associated with the upregulation of c-MYC interacting genes and EMT-like signature. Oncotarget (2016) 0.75
The development of a malignant tumor is due to a desperate asexual self-cloning process in which cancer stem cells develop the ability to mimic the genetic program of germline cells. Intrinsically Disord Proteins (2014) 0.75
The "virgin birth", polyploidy, and the origin of cancer. Oncoscience (2014) 0.75
MYC Modulation around the CDK2/p27/SKP2 Axis. Genes (Basel) (2017) 0.75
WAF1, a potential mediator of p53 tumor suppression. Cell (1993) 38.72
Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol (1992) 34.17
p53, the cellular gatekeeper for growth and division. Cell (1997) 31.04
The retinoblastoma protein and cell cycle control. Cell (1995) 20.21
Cell cycle checkpoints: preventing an identity crisis. Science (1996) 13.74
Feedback control of mitosis in budding yeast. Cell (1991) 12.39
S. cerevisiae genes required for cell cycle arrest in response to loss of microtubule function. Cell (1991) 11.56
Mutations of mitotic checkpoint genes in human cancers. Nature (1998) 11.20
Cell cycle control and cancer. Science (1994) 10.90
Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev (1998) 9.03
Monoclonal antibodies to mitotic cells. Proc Natl Acad Sci U S A (1983) 6.74
Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol (1995) 6.41
Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science (1992) 6.40
Identification of a human mitotic checkpoint gene: hsMAD2. Science (1996) 6.37
Kinetochore localization of murine Bub1 is required for normal mitotic timing and checkpoint response to spindle damage. Cell (1997) 6.36
Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes. Mol Cell Biol (1995) 6.26
Association of spindle assembly checkpoint component XMAD2 with unattached kinetochores. Science (1996) 6.10
Association of human cyclin E with a periodic G1-S phase protein kinase. Science (1992) 5.98
Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc Natl Acad Sci U S A (1994) 5.11
The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins. Cell (1998) 4.52
Cdc25 cell-cycle phosphatase as a target of c-myc. Nature (1996) 4.23
The human homologue of Bub3 is required for kinetochore localization of Bub1 and a Mad3/Bub1-related protein kinase. J Cell Biol (1998) 4.23
When checkpoints fail. Cell (1997) 4.21
Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays. Cancer Res (1993) 4.11
Cyclin E controls S phase progression and its down-regulation during Drosophila embryogenesis is required for the arrest of cell proliferation. Cell (1994) 4.07
A p53-dependent mouse spindle checkpoint. Science (1995) 4.01
Regulation of the cyclin E gene by transcription factor E2F1. Proc Natl Acad Sci U S A (1995) 3.95
Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Mol Cell Biol (1998) 3.88
Ordering S phase and M phase in the cell cycle. Cell (1994) 3.87
Different roles for cyclins D1 and E in regulation of the G1-to-S transition. Mol Cell Biol (1995) 3.41
Cyclin E-induced S phase without activation of the pRb/E2F pathway. Genes Dev (1997) 3.02
Myc and the cell cycle. Front Biosci (1998) 2.88
The molecular role of Myc in growth and transformation: recent discoveries lead to new insights. FASEB J (1998) 2.86
Viewpoint: putting the cell cycle in order. Science (1996) 2.80
mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol (1996) 2.78
Growth arrest by the cyclin-dependent kinase inhibitor p27Kip1 is abrogated by c-Myc. EMBO J (1996) 2.59
The p53-dependent G1 cell cycle checkpoint pathway and ataxia-telangiectasia. Cancer Res (1994) 2.41
A unique glucose-dependent apoptotic pathway induced by c-Myc. Proc Natl Acad Sci U S A (1998) 2.34
Myc target genes. Trends Biochem Sci (1997) 2.34
Expression of Bcl-xL and loss of p53 can cooperate to overcome a cell cycle checkpoint induced by mitotic spindle damage. Genes Dev (1996) 2.30
Neoplastic transformation by the human gene N-myc. Mol Cell Biol (1987) 2.17
E2F and cell proliferation: a world turned upside down. Cell (1996) 2.16
Cell line-specific differences in the control of cell cycle progression in the absence of mitosis. Proc Natl Acad Sci U S A (1990) 2.10
Microtubule dependency of p34cdc2 inactivation and mitotic exit in mammalian cells. J Cell Biol (1994) 2.01
Cell cycle regulation of the murine cyclin E gene depends on an E2F binding site in the promoter. Mol Cell Biol (1996) 1.97
Identification of a Myc-dependent step during the formation of active G1 cyclin-cdk complexes. EMBO J (1995) 1.92
DNA rereplication in the presence of mitotic spindle inhibitors in human and mouse fibroblasts lacking either p53 or pRb function. Cancer Res (1997) 1.88
Cyclin E and c-Myc promote cell proliferation in the presence of p16INK4a and of hypophosphorylated retinoblastoma family proteins. EMBO J (1997) 1.81
c-Myc and apoptosis. Biochim Biophys Acta (1995) 1.80
E2F-induced S phase requires cyclin E. Genes Dev (1996) 1.71
A link between increased transforming activity of lymphoma-derived MYC mutant alleles, their defective regulation by p107, and altered phosphorylation of the c-Myc transactivation domain. Mol Cell Biol (1995) 1.59
p53 and pRb prevent rereplication in response to microtubule inhibitors by mediating a reversible G1 arrest. Cancer Res (1998) 1.59
S-Phase entry upon ectopic expression of G1 cyclin-dependent kinases in the absence of retinoblastoma protein phosphorylation. Curr Biol (1997) 1.48
Myc activation of cyclin E/Cdk2 kinase involves induction of cyclin E gene transcription and inhibition of p27(Kip1) binding to newly formed complexes. Oncogene (1997) 1.35
C-myc overexpression and p53 loss cooperate to promote genomic instability. Oncogene (1999) 1.34
Repression of c-Myc responsive genes in cycling cells causes G1 arrest through reduction of cyclin E/CDK2 kinase activity. Oncogene (1997) 1.27
Oncogene-induced basement membrane invasiveness in human mammary epithelial cells. Clin Exp Metastasis (1994) 1.24
c-Myc overexpression associated DHFR gene amplification in hamster, rat, mouse and human cell lines. Oncogene (1996) 1.19
High-level expression of c-H-ras1 fails to fully transform rat-1 cells. Mol Cell Biol (1988) 1.03
Ploidy and karyotypic alterations associated with early events in the development of hepatocarcinogenesis in transgenic mice harboring c-myc and transforming growth factor alpha transgenes. Cancer Res (1996) 1.01
Cyclins, Cdks, and cyclin kinase inhibitors. Cold Spring Harb Symp Quant Biol (1994) 0.99
A single Cys706 to Phe substitution in the retinoblastoma protein causes the loss of binding to SV40 T antigen. Cell Growth Differ (1990) 0.96
Mammalian BUB1 protein kinases: map positions and in vivo expression. Genomics (1997) 0.88
Cell-substratum interactions mediate oncogene-induced phenotype of lung cancer cells. Cell Growth Differ (1996) 0.81
c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci U S A (1997) 5.43
An amino-terminal c-myc domain required for neoplastic transformation activates transcription. Mol Cell Biol (1990) 4.24
Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem (2000) 3.74
Identification of CDK4 as a target of c-MYC. Proc Natl Acad Sci U S A (2000) 3.38
Translocations involving c-myc and c-myc function. Oncogene (2001) 3.21
Neoplastic transformation of RK3E by mutant beta-catenin requires deregulation of Tcf/Lef transcription but not activation of c-myc expression. Mol Cell Biol (1999) 3.08
Max: functional domains and interaction with c-Myc. Genes Dev (1992) 2.88
Hypoxia inhibits G1/S transition through regulation of p27 expression. J Biol Chem (2000) 2.70
Identification of c-myc responsive genes using rat cDNA microarray. Cancer Res (2000) 2.62
c-Myc is glycosylated at threonine 58, a known phosphorylation site and a mutational hot spot in lymphomas. J Biol Chem (1995) 2.47
A unique glucose-dependent apoptotic pathway induced by c-Myc. Proc Natl Acad Sci U S A (1998) 2.34
Participation of cyclin A in Myc-induced apoptosis. Proc Natl Acad Sci U S A (1994) 2.34
A potential transcriptional activation element in the p53 protein. Oncogene (1990) 2.07
Identification of putative c-Myc-responsive genes: characterization of rcl, a novel growth-related gene. Mol Cell Biol (1997) 1.92
Characterization of nucleophosmin (B23) as a Myc target by scanning chromatin immunoprecipitation. J Biol Chem (2001) 1.89
Induction of ribosomal genes and hepatocyte hypertrophy by adenovirus-mediated expression of c-Myc in vivo. Proc Natl Acad Sci U S A (2000) 1.89
Binding and suppression of the Myc transcriptional activation domain by p107. Science (1994) 1.84
A link between increased transforming activity of lymphoma-derived MYC mutant alleles, their defective regulation by p107, and altered phosphorylation of the c-Myc transactivation domain. Mol Cell Biol (1995) 1.59
Glycosylation of the c-Myc transactivation domain. Proc Natl Acad Sci U S A (1995) 1.58
Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease. Ann Intern Med (1998) 1.51
Inversion of aerotactic response in Escherichia coli deficient in cheB protein methylesterase. J Bacteriol (1986) 1.47
Activation domains of L-Myc and c-Myc determine their transforming potencies in rat embryo cells. Mol Cell Biol (1992) 1.39
Transformation by the Bmi-1 oncoprotein correlates with its subnuclear localization but not its transcriptional suppression activity. Mol Cell Biol (1996) 1.36
Identification of a large Myc-binding protein that contains RCC1-like repeats. Proc Natl Acad Sci U S A (1998) 1.34
Function of the c-Myc oncoprotein. FASEB J (1992) 1.34
Oxygen as attractant and repellent in bacterial chemotaxis. J Bacteriol (1987) 1.34
Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res (1998) 1.33
The hepatitis B virus X protein increases the cellular level of TATA-binding protein, which mediates transactivation of RNA polymerase III genes. Mol Cell Biol (1995) 1.32
Severe liver trauma in the face of coagulopathy. A case for temporary packing and early reexploration. Am J Surg (1982) 1.30
Tumor induction by the c-Myc target genes rcl and lactate dehydrogenase A. Cancer Res (2000) 1.29
Opposite orientations of DNA bending by c-Myc and Max. Proc Natl Acad Sci U S A (1992) 1.27
Myc target transcriptomes. Curr Top Microbiol Immunol (2006) 1.23
Differential binding of c-Myc and Max to nucleosomal DNA. Mol Cell Biol (1994) 1.19
Disorganization of cultured vascular endothelial cell monolayers by fibrinogen fragment D. Science (1985) 1.19
Association of methionyl-tRNA synthetase with detergent-insoluble components of the rough endoplasmic reticulum. J Cell Biol (1983) 1.17
The upstream stimulatory factor binds to and activates the promoter of the rat class I alcohol dehydrogenase gene. J Biol Chem (1991) 1.17
Localization of a fibrinogen calcium binding site between gamma-subunit positions 311 and 336 by terbium fluorescence. J Biol Chem (1985) 1.16
Max and inhibitory c-Myc mutants induce erythroid differentiation and resistance to apoptosis in human myeloid leukemia cells. Oncogene (1997) 1.15
MXI1, a putative tumor suppressor gene, suppresses growth of human glioblastoma cells. Cancer Res (1997) 1.15
Definition of the activities and properties of c-myc required to inhibit cell differentiation. Cell Growth Differ (1990) 1.14
Elevated extracellular calcium can prevent apoptosis via the calcium-sensing receptor. Biochem Biophys Res Commun (1998) 1.13
Nuclear punctate distribution of ALL-1 is conferred by distinct elements at the N terminus of the protein. Proc Natl Acad Sci U S A (1997) 1.12
Detection and modulation in vivo of helix-loop-helix protein-protein interactions. J Biol Chem (1993) 1.11
A novel c-Myc-responsive gene, JPO1, participates in neoplastic transformation. J Biol Chem (2001) 1.08
A link between c-Myc-mediated transcriptional repression and neoplastic transformation. J Clin Invest (1996) 1.06
Cyclin A links c-Myc to adhesion-independent cell proliferation. J Biol Chem (1995) 1.05
The basic helix-loop-helix protein upstream stimulating factor regulates the cardiac ventricular myosin light-chain 2 gene via independent cis regulatory elements. Mol Cell Biol (1994) 1.04
Acute pancreatitis: a complication of Foley catheter gastrostomy. J Natl Med Assoc (1986) 1.04
Arsenic inhibition of telomerase transcription leads to genetic instability. J Clin Invest (2001) 1.03
Cancer genetics: tumor suppressor meets oncogene. Curr Biol (1999) 1.02
B-myc inhibits neoplastic transformation and transcriptional activation by c-myc. Mol Cell Biol (1993) 1.01
Pancytopenia secondary to oxalosis in a 23-year-old woman. Blood (1998) 0.92
Multienzyme complex of aminoacyl-tRNA synthetases: an essence of being eukaryotic. Biochem J (1986) 0.92
Localization of the human Mxi1 transcription factor gene (MXI1) to chromosome 10q24-q25. Genomics (1994) 0.91
Rat liver histidyl-tRNA synthetase. Purification and inhibition by the myositis-specific anti-Jo-1 autoantibody. Biochem Biophys Res Commun (1984) 0.90
Clustered mutations in the transcriptional activation domain of Myc in 8q24 translocated lymphomas and their functional consequences. Curr Top Microbiol Immunol (1995) 0.90
c-Myc suppresses the tumorigenicity of lung cancer cells and down-regulates vascular endothelial growth factor expression. Cancer Res (2000) 0.89
Human T-cell leukemia virus type I tax masks c-Myc function through a cAMP-dependent pathway. J Biol Chem (1996) 0.89
Mammalian BUB1 protein kinases: map positions and in vivo expression. Genomics (1997) 0.88
The use of gated radionuclide angiography in the diagnosis of cardiac contusion. Ann Emerg Med (1984) 0.88
Higher eukaryotic aminoacyl-tRNA synthetases in physiologic and pathologic states. Mol Cell Biochem (1986) 0.88
Genomic organization of human MXI1, a putative tumor suppressor gene. Genomics (1996) 0.86
17beta-estradiol inhibits apoptosis of endothelial cells. Biochem Biophys Res Commun (1997) 0.86
Cell density and paradoxical transcriptional properties of c-Myc and Max in cultured mouse fibroblasts. J Clin Invest (1995) 0.84
Affinity chromatography of rat liver aminoacyl-tRNA synthetase complex. Biochem Biophys Res Commun (1978) 0.83
c-myc box II mutations in Burkitt's lymphoma-derived alleles reduce cell-transformation activity and lower response to broad apoptotic stimuli. Oncogene (2001) 0.83
High molecular weight complexes of eukaryotic aminoacyl-tRNA synthetases. Int J Biochem (1982) 0.81
Trauma of the colon: early drop-back of exteriorized repair. Arch Surg (1982) 0.81
Polymerization defect of fibrinogen Baltimore III due to a gamma Asn308----Ile mutation. Blood (1990) 0.81
Interactions of aminoacyl-tRNA synthetases in high-molecular-weight multienzyme complexes from rat liver. Biochim Biophys Acta (1985) 0.81
A new complication of percutaneous endoscopic gastrostomy. Am J Gastroenterol (1988) 0.81
Association of the decreased expression of alpha3beta1 integrin with the altered cell: environmental interactions and enhanced soft agar cloning ability of c-myc-overexpressing small cell lung cancer cells. Cancer Res (1998) 0.80
The ear lobe crease: chromosomes, acupuncture, and atherosclerosis. Lancet (1984) 0.79
Do products of the myc proto-oncogene play a role in transcriptional regulation of the prothymosin alpha gene? Mol Cell Biol (1995) 0.79
High molecular mass amino acyl-tRNA synthetase complexes in eukaryotes. FEBS Lett (1982) 0.79
Nutritional amblyopia. Folic acid, vitamin B-12, and other vitamins. Retina (1982) 0.78
C-Myc transrepression and cell transformation. Curr Top Microbiol Immunol (1997) 0.78
Multienzyme complexes of eukaryotic aminoacyl-tRNA synthetases. Biosci Rep (1983) 0.78
Fibrinogen Baltimore I: polymerization defect associated with a gamma 292Gly----Val (GGC----GTC) mutation. Blood (1990) 0.77
Application of a nitrocellulose immunoassay for quantitation of proteins secreted in culture media. Anal Biochem (1986) 0.77
A strategy to identify differentially expressed genes using representational difference analysis and cDNA arrays. Anal Biochem (2001) 0.77
Myc target genes in neoplastic transformation. Curr Top Microbiol Immunol (1997) 0.76
DNA binding by the Myc oncoproteins. Cancer Treat Res (1992) 0.76
Structural organization of high-Mr mammalian aminoacyl-tRNA synthetases. Comparison of multi-enzyme complexes from different sources. Mol Cell Biochem (1984) 0.76
High molecular weight complex formation of rat liver lysyl-tRNA synthetase reduces enzyme lability to thermal inactivation. Biochem Biophys Res Commun (1982) 0.76
Histidyl-tRNA synthetase, the myositis Jo-1 antigen, is cytoplasmic and unassociated with the cytoskeletal framework. Exp Cell Res (1986) 0.76
Does gastrostomy and fundoplication prevent aspiration pneumonia in mentally retarded persons? Am J Ment Retard (1989) 0.76
Identity of the ubiquitous eukaryotic ring-shaped miniparticle. Cell Biol Int Rep (1984) 0.76
Hydrodynamic properties and structure of the rat liver 12 S arginyl- and lysyl-tRNA synthetase complex. Biochem Biophys Res Commun (1983) 0.76
Stimulation of fibrinogen synthesis in cultured rat hepatocytes by fibrinogen degradation product fragment D. Proc Natl Acad Sci U S A (1989) 0.75
Transient global amnesia after sex. Lancet (1998) 0.75
Protective effect of divalent cations in the plasmin degradation of fibrinogen. Arch Biochem Biophys (1985) 0.75
Polymyositis and molecular mimicry. Lancet (1986) 0.75
Horseshoe kidney and renovascular hypertension responsive to percutaneous transluminal angioplasty. Ann Intern Med (1985) 0.75
A case of agnogenic myeloid metaplasia evolving into acute myelogenous leukemia associated with the development of trisomy 11 in bone marrow cells. Am J Hematol (1985) 0.75
Splenic function following experimental dearterialization injury in the suckling rat. J Pediatr Surg (1978) 0.75